Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Is a Surprise in the Cards for Teva (TEVA) in Q2 Earnings?

While the inclusion of sales from Actavis Generics acquisition may continue to pull up Teva Pharmaceutical Industries Ltd.'s (TEVA) sales, its generic segment may see weakness.

    Nektar's NKTR-181 Positive in Human Abuse Potential Study

    Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.

      AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

      AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

        Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK

        Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium).

          VIVUS Settles with Teva on Weight Management Drug Generic

          VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.

            Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA

            Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar to Roche Holding AG's (RHHBY) Rituxan (rituximab).

              Alder's Shares Dip Despite Positive Migraine Trial Results

              Alder Biopharmaceuticals, Inc.'s (ALDR) shares plummeted almost 28% despite the announcement of positive top line results from phase III study, evaluating its lead pipeline candidate eptinezumab for prevention of frequent episodic migraine.

                Teva/Xenon Nerve Pain Candidate Fails in Phase II Study

                Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.

                  Allergan Continues to Focus on Acquisitions and Branded Unit

                  We issued an updated research report on Allergan plc (AGN) on Jun 23.

                    Glaxo's (GSK) Shingles Candidate Phase III Data Positive

                    GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

                      Pfizer & Lilly Get Fast Track Designation for Pain Candidate

                      Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

                        Teva Migraine Candidate Succeeds in Second Phase III Study

                        Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.

                          Regeneron Announces Positive Data on Carcinoma Candidate

                          Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

                            Teva's Migraine Candidate TEV-48125 Positive in Phase III

                            Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).

                              Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab

                              Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.

                                Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA

                                Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.

                                  Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

                                  Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.

                                    Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint

                                    Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies

                                      Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls

                                      Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.

                                        Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

                                        Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

                                          Teva (TEVA) Q1 Earnings In-Line, Sales Miss, Shares Up

                                          Teva???s first quarter earnings (including equity compensation expenses), came in at $1.03 per share, in-line with the consensus estimate.

                                            Swarup Gupta headshot

                                            Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?

                                            Mylan and Teva are scheduled to report on May 10 and May 11

                                              Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View

                                              Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.

                                                Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?

                                                Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11

                                                  Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?

                                                  Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.